RecruitingNot Applicable

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

Germany842 participantsStarted 2024-09-26

Plain-language summary

The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneous (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of MS * RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 * First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab Exclusion Criteria: * Participation in interventional studies investigating DMTs for MS * Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site * Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®) * Severe psychiatric disability * Pregnant women

What they're measuring

Number of Participants Their Level of by Satisfaction With Ocrelizumab SC After 12 Months Assessed Using TASQ-SC

Timeframe: Month 12

Trial details

NCT IDNCT06780150

SponsorHoffmann-La Roche

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-03-31

Contact for this trial

Reference Study ID Number: ML45551 https://forpatients.roche.com/

888-662-6728 (U.S. Only) global-roche-genentech-trials@gene.com

View on ClinicalTrials.gov More Multiple Sclerosis trials